GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lannett Co Inc (OTCPK:LCINQ) » Definitions » Net-Net Working Capital

Lannett Co (Lannett Co) Net-Net Working Capital : $-56.01 (As of Mar. 2023)


View and export this data going back to 1994. Start your Free Trial

What is Lannett Co Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

Lannett Co's Net-Net Working Capital for the quarter that ended in Mar. 2023 was $-56.01.

The industry rank for Lannett Co's Net-Net Working Capital or its related term are showing as below:

LCINQ's Price-to-Net-Net-Working-Capital is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.78
* Ranked among companies with meaningful Price-to-Net-Net-Working-Capital only.

Lannett Co Net-Net Working Capital Historical Data

The historical data trend for Lannett Co's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lannett Co Net-Net Working Capital Chart

Lannett Co Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Net-Net Working Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only -66.08 -54.47 -53.98 -49.43 -54.82

Lannett Co Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -52.18 -54.82 -56.23 -56.94 -56.01

Competitive Comparison of Lannett Co's Net-Net Working Capital

For the Drug Manufacturers - Specialty & Generic subindustry, Lannett Co's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Lannett Co's Price-to-Net-Net-Working-Capital Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Lannett Co's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where Lannett Co's Price-to-Net-Net-Working-Capital falls into.



Lannett Co Net-Net Working Capital Calculation

Lannett Co's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Jun. 2022 is calculated as

Net-Net Working Capital(A: Jun. 2022 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(87.854+0.75 * 56.241+0.5 * 95.158-735.498
-0-0)/10.1761
=-54.82

Lannett Co's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2023 is calculated as

Net-Net Working Capital(Q: Mar. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(46.54+0.75 * 68.153+0.5 * 90.805-746.883
-0-0)/10.7803
=-56.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


Lannett Co  (OTCPK:LCINQ) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


Lannett Co Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of Lannett Co's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Lannett Co (Lannett Co) Business Description

Traded in Other Exchanges
N/A
Address
1150 Northbrook Drive, Suite 155, Trevose, PA, USA, 19053
Lannett Co Inc develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products. It offers solid oral, extended-release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. In addition, the company also provides its products for various medical indications comprising glaucoma, gastrointestinal, migraine, obesity, respiratory, and others. It operates in the segment of generic pharmaceuticals. Its customers include generic pharmaceutical distributors, drug wholesalers, chain drug stores, private label distributors, mail-order pharmacies, and others.
Executives
John C Chapman director 9000 STATE ROAD, PHILADELPHIA PA 19136
Timothy C Crew officer: Chief Executive Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
Patrick G Lepore director 17-17 ROUTE 208 N, FAIRLAWN NJ 07410
Melissa Rewolinski director 9000 STATE ROAD, PHILADELPHIA PA 19136
Jeffrey Farber officer: Secretary
Samuel H Israel officer: Chief Legal Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
John Abt officer: Vice President of Quality 9000 STATE ROAD, PHILADELPHIA PA 19136
John Kozlowski officer: Chief Operating Officer 9000 STATE ROAD, PHILADELPHIA PA 19136
David A Drabik director 9000 STATE RD, PHILADELPHIA PA 19136
Paul Taveira director 9000 STATE ROAD, PHILADELPHIA PA 19136
Albert Iii Paonessa director 9852 NW 2ND COURT, PLANTATION FL 33324
Kevin Smith other: Vice President
Maureen Cavanaugh officer: Senior Vice President and CCOO 9000 STATE ROAD, PHILADELPHIA PA 19136
David Farber officer: Treasurer
Arthur P Bedrosian officer: President P O BOX D 1400, POMONA NY 10970